Guardian Partners Inc. bought a new position in shares of AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund bought 1,786,414 shares of the company's stock, valued at approximately $5,413,000. Guardian Partners Inc. owned 0.60% of AbCellera Biologics at the end of the most recent quarter.
Other institutional investors have also recently made changes to their positions in the company. State Street Corp raised its stake in AbCellera Biologics by 1.5% during the third quarter. State Street Corp now owns 323,229 shares of the company's stock worth $840,000 after buying an additional 4,679 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of AbCellera Biologics by 10.5% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 62,629 shares of the company's stock worth $184,000 after acquiring an additional 5,955 shares in the last quarter. State of New Jersey Common Pension Fund D acquired a new position in shares of AbCellera Biologics in the 4th quarter valued at about $36,000. B. Riley Wealth Advisors Inc. boosted its position in shares of AbCellera Biologics by 58.1% during the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 34,000 shares of the company's stock valued at $88,000 after purchasing an additional 12,500 shares in the last quarter. Finally, IMG Wealth Management Inc. acquired a new stake in AbCellera Biologics during the fourth quarter worth approximately $56,000. Institutional investors own 61.42% of the company's stock.
Wall Street Analyst Weigh In
Several analysts have recently commented on ABCL shares. Benchmark reaffirmed a "hold" rating on shares of AbCellera Biologics in a research report on Monday, March 3rd. Stifel Nicolaus dropped their price objective on shares of AbCellera Biologics from $12.00 to $10.00 and set a "buy" rating on the stock in a research note on Friday, February 28th. Finally, KeyCorp lowered their price target on AbCellera Biologics from $5.00 to $4.00 and set an "overweight" rating for the company in a research report on Wednesday, January 8th.
Get Our Latest Research Report on AbCellera Biologics
AbCellera Biologics Stock Performance
ABCL traded down $0.06 during midday trading on Thursday, reaching $2.36. The company had a trading volume of 2,769,474 shares, compared to its average volume of 2,410,911. AbCellera Biologics Inc. has a 12-month low of $2.11 and a 12-month high of $4.75. The business has a 50-day moving average price of $2.87 and a two-hundred day moving average price of $2.82. The stock has a market cap of $703.25 million, a PE ratio of -3.87 and a beta of 0.45.
AbCellera Biologics Profile
(
Free Report)
AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.
See Also
Before you consider AbCellera Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbCellera Biologics wasn't on the list.
While AbCellera Biologics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
